Clinical Trials Logo

Filter by:
NCT ID: NCT00684333 Suspended - Healthy Clinical Trials

Safety and Efficacy of EZ-Ject Injector a Pain-Free Subcutaneous Automatic Injection in Healthy Volunteers

Start date: June 2009
Phase: N/A
Study type: Interventional

Subcutaneous injections are a widely used method for drug delivery. One of its major drawbacks is the pain inflicted during the process. Sindolor has developed the chemical-free EZ-Ject Injector device, based on employing cutaneous local anesthesia on the injection site by an electronic anesthetic system. The purpose of this study is to determine the safety and efficacy of the EZ-Ject for subcutaneous injections.

NCT ID: NCT00683969 Completed - Clinical trials for Myasthenia Gravis, Generalized

A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis

Start date: August 2004
Phase: Phase 3
Study type: Interventional

The efficacy and safety of CellCept (1g po, bid for 36 weeks) will be assessed in patients with myasthenia gravis receiving prednisone, or other corticosteroids. During the study, patients will undergo gradual corticosteroid dose reduction, if they respond to treatment. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

NCT ID: NCT00683930 Completed - Clinical trials for Pemphigus Vulgaris (PV)

A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)

Start date: May 2004
Phase: Phase 3
Study type: Interventional

This study was designed to assess the efficacy and safety of CellCept (1 g or 1.5 g orally twice daily for 52 weeks) in patients with pemphigus vulgaris receiving prednisone or other corticosteroids. During the study, patients had their corticosteroid dose gradually reduced if they responded to treatment. The anticipated time on study treatment was 12 months, and the target sample size was <100 individuals.

NCT ID: NCT00683696 Terminated - Heart Failure Clinical Trials

Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)

EchoCRT
Start date: August 2008
Phase: Phase 2/Phase 3
Study type: Interventional

The EchoCRT trial evaluates the effects of Cardiac Resynchronization Therapy (CRT) on mortality and morbidity of subjects with heart failure due to left ventricular systolic dysfunction, already receiving optimized HF medication, with a narrow QRS width (< 130 ms) and echocardiographic evidence of ventricular dyssynchrony.

NCT ID: NCT00683657 Completed - Type 2 Diabetes Clinical Trials

Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone

Start date: July 2008
Phase: Phase 3
Study type: Interventional

This protocol will compare 24 hour glucose control for subject taking saxagliptin and metformin extended release (XR) versus metformin XR alone

NCT ID: NCT00682500 Terminated - Clinical trials for Respiratory Distress Syndrome, Adult

Calfactant for Direct Acute Respiratory Distress Syndrome

CARDS
Start date: May 2008
Phase: Phase 3
Study type: Interventional

This study will determine if administration of an suspension of calfactant, a lung surfactant, intratracheally in patients with Direct Acute Respiratory Distress Syndrome within 48 hours of requiring mechanical ventilation can decrease the mortality in patients with lethal disease and shorten the course of respiratory failure in patients with sub-lethal disease.

NCT ID: NCT00682487 Completed - Clinical trials for Acute Myocardial Infarction

Hair Cortisol and the Risk of Acute Myocardial Infarction

Start date: June 2008
Phase: N/A
Study type: Observational

Aim of the study: To evaluate whether hair cortisol levels are elevated in patients admitted with acute MI compared to controls. Study steps: 1. Introduction of the study to the participants and inform consent signing 2. Collection of clinical and demographic data 3. Scalp hair sampling- samples will be sent for laboratory analysis 4. Analysis of the results

NCT ID: NCT00681096 Not yet recruiting - Low Back Pain Clinical Trials

Causes of Low Back Pain in Nurses in Israeli Hospitals

Start date: June 2008
Phase: N/A
Study type: Observational

An examination of the various factors that cause lower back pain in nurses in four hospitals in Israel such as; socio-demographic, professional, posture while ambulating patients and job environment.

NCT ID: NCT00680901 Active, not recruiting - Clinical trials for Neoplasms, Gastrointestinal Tract

LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

Start date: June 4, 2008
Phase: Phase 3
Study type: Interventional

This is an international multi-center trial that will enroll patients with locally advanced, unresectable, or metastatic gastric, esophageal, or gastro-esophageal junction cancer whose tumors have amplification of the ErbB2 (HER2) gene. The trial will investigate whether lapatinib, when added to the chemotherapy regimen, capecitabine plus oxaliplatin (CapeOx), extends the time to progression and overall survival. Tumor ErbB2 (HER2) status must be known before trial entry. CapeOx is administered to all patients, and patients will be randomly assigned to receive either lapatinib or placebo.

NCT ID: NCT00680186 Completed - Thromboembolism Clinical Trials

Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)

RE-COVER II
Start date: April 2008
Phase: Phase 3
Study type: Interventional

The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate 150 mg bid administered orally and warfarin Pro re nata (As needed/PRN) to maintain an International Normalised Ratio (INR) of 2.0-3.0 for 6 month treatment of acute symptomatic VTE. The primary objective is to investigate the efficacy of dabigatran compared to warfarin during the 6 month treatment period. The investigation of other selected efficacy aspects and safety are regarded as secondary objective of this trial.